Skip to main content

Metamucil MultiHealth Fiber Sugar-free Disease Interactions

There are 4 disease interactions with Metamucil MultiHealth Fiber Sugar-free (psyllium).

Major

Bulk producing laxatives (applies to Metamucil MultiHealth Fiber Sugar-free) intestinal obstruction

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction. Bulk producing laxatives can exacerbate these conditions.

References (3)
  1. (2001) "Product Information. FiberCon (polycarbophil)." Lederle Laboratories
  2. (2001) "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals
  3. (2001) "Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc
Major

Laxatives (applies to Metamucil MultiHealth Fiber Sugar-free) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References (6)
  1. (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
  4. (2001) "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc
  5. (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
  6. (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Major

Laxatives (applies to Metamucil MultiHealth Fiber Sugar-free) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References (8)
  1. (2001) "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc
  2. "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet
  3. "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb
  4. (2001) "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet
  5. (2001) "Product Information. Citrucel (methylcellulose)." SmithKline Beecham
  6. (2001) "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc
  7. (2022) "Product Information. SenoSol-X (senna)." Apothecon Inc
  8. (2010) "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories
Moderate

Bulk producing laxatives (applies to Metamucil MultiHealth Fiber Sugar-free) renal dysfunction

Moderate Potential Hazard, High plausibility.

Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose. Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.

References (2)
  1. (2001) "Product Information. FiberCon (polycarbophil)." Lederle Laboratories
  2. (2001) "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals

Switch to consumer interaction data

Metamucil MultiHealth Fiber Sugar-free drug interactions

There are 29 drug interactions with Metamucil MultiHealth Fiber Sugar-free (psyllium).

Metamucil MultiHealth Fiber Sugar-free alcohol/food interactions

There is 1 alcohol/food interaction with Metamucil MultiHealth Fiber Sugar-free (psyllium).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer